Temper Buzz About the First Oral GLP-1 Agonist, Rybelsus

June 2020

Rybelsus (semaglutide) will be the first ORAL GLP-1 agonist for type 2 diabetes...it's a tablet version of injectable Ozempic.

Glucagon-like peptide-1 (GLP-1) is inactivated in the stomach.

That's why other GLP-1 agonists...Bydureon (exenatide), Trulicity (dulaglutide), Victoza (liraglutide), etc...are injected.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Immunizations Keep Immunizations on Track During COVID-19
Infectious Diseases Put Treatments for COVID-19 in Perspective
Diabetes Temper Buzz About the First Oral GLP-1 Agonist, Rybelsus
Dermatology Manage Skin Irritation Due to Handwashing and PPE
Infectious Diseases Settle Debate About Vancomycin or Fidaxomicin for C. diff
Opioids Avoid Switching Methadone Products in Patients With Opioid Use Disorder
Communication Enhance Your Telecommunication Skills
Anticoagulants Expect to See DOACs for Venous Thromboembolism Due to Cancer
Practice Weigh the Situation When Patients Ask About Expiration Dates
Poison Prevention Provide Strategies to Prevent Poisonings